Literature DB >> 11113673

Intrathoracic muscle flap transposition in the treatment of fibrocavernous tuberculosis.

Y L Tseng1, M H Wu, M Y Lin, W W Lai.   

Abstract

BACKGROUND AND
OBJECTIVE: Conventionally, pulmonary resection with thoracoplasty is used to treat fibrocavernous complication of pulmonary tuberculosis. This operation is usually bloody, time-consuming with complicated postoperative course. To prevent massive blood loss and preserved pulmonary function, a more simplified operative procedure, cavernostomy combined intrathoracic muscle flap transposition was used and the outcome was evaluated in this study.
DESIGN: Retrospective review.
METHODOLOGY: Between December 1989 and June 1996, a total of ten patients with fibrocavernous pulmonary tuberculosis were managed using cavernostomy combined with intrathoracic muscle flap transposition. Five of them had concomitant aspergilloma within the cavity while three had multiple drug resistant pulmonary tuberculosis. The muscle flap was used to plombage the cavity and reinforce the closure of bronchopleural fistula after cavernostomy.
RESULTS: Six postoperative complications occurred in five patients, including reformation of cavity (2), bronchopleurocutaneous fistulae (3), and postoperative bleeding (1). The success or failure of intrathoracic muscle flap transposition on patients with fibrocavernous tuberculosis was significantly correlated with the size of the cavity (194.0+/-11.2 vs. 283.0+/-44.6 cm(3), P=0.016) and the number of bronchopleural fistulae (1.6+/-0.4 vs. 4.0+/-0.4, P=0.008). There was no operative death and in long term follow-up, there was no recurrence of hemoptysis or deterioration of pulmonary function in the successful group of patients.
CONCLUSIONS: Cavernostomy combined with intrathoracic muscle flap transposition can be used to treat well-selected fibrocavernous pulmonary tuberculosis patients, except on patients with large size cavity, multiple bronchopleural fistulae or multiple drug resistance tuberculosis.

Entities:  

Mesh:

Year:  2000        PMID: 11113673     DOI: 10.1016/s1010-7940(00)00594-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  Aspergilloma and the surgeon.

Authors:  Loven Moodley; Jehron Pillay; Keertan Dheda
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

2.  Surgical treatment for pulmonary aspergilloma: a 35-year experience in the Chinese population.

Authors:  Qian-Kun Chen; Ge-Ning Jiang; Jia-An Ding
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-11

3.  Hemoptysis from complex pulmonary aspergilloma treated by cavernostomy and thoracoplasty.

Authors:  Nguyen Truong Giang; Le Tien Dung; Nguyen Thanh Hien; Truong Thanh Thiet; Phan Sy Hiep; Nguyen The Vu; Dinh Cong Pho; Nguyen Van Nam; Pham Ngoc Hung
Journal:  BMC Surg       Date:  2019-12-05       Impact factor: 2.102

4.  Surgical Outcome of Chronic Pulmonary Aspergilloma: An Experience from Two Tertiary Referral Hospitals in Addis Ababa, Ethiopia.

Authors:  Berhanu N Alemu
Journal:  Ethiop J Health Sci       Date:  2020-07-01

5.  The Role of Video-Assisted Thoracoscopic Therapeutic Resection for Medically Failed Pulmonary Tuberculosis.

Authors:  Yau-Lin Tseng; Jia-Ming Chang; Yi-Sheng Liu; Lili Cheng; Ying-Yuan Chen; Ming-Ho Wu; Chung-Lan Lu; Yi-Ting Yen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

6.  From one incision to one port: The surgical technique and the evolution of segmentectomy in patients with pulmonary tuberculosis.

Authors:  Yau-Lin Tseng; Chao-Chun Chang; Ying-Yuan Chen; Yi-Sheng Liu; Lili Cheng; Jia-Ming Chang; Ming-Ho Wu; Yi-Ting Yen
Journal:  PLoS One       Date:  2018-05-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.